Save the PARIS Test Before 2025 Ends

At the end of 2025, we will no longer have access to functional precision medicine for patients without your support. 

Every cancer is unique. So is every patient. At Cure First, our mission is to make the PARIS Test accessible to patients with hard-to-treat cancers that have exhausted standard options and reveal the treatments most likely to work next.

The PARIS Test uses live tumor cells to evaluate how a patient's cancer responds to a broad range of potential treatments in vitro. By pairing test results with molecular profiling, clinicians gain a personalized view of which therapies may offer the greatest benefit for each patient.

Our goal is simple: Give patients and their care teams more insight, more clarity, and more possibilities.